Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure
Status:
Not yet recruiting
Trial end date:
2024-08-07
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is the most common arrhythmia, which leads to reduced cardiac output
and promotes the occurrence of heart failure, and abnormal hemodynamic changes in the left
atrium induce thrombosis, which seriously reduces the quality of life, and even leads to
death. For patients who need cardiac surgery combined with the Cox-Maze IV (CMIV) surgical
ablation, oral amiodarone postoperatively for three consecutive months was recommended as the
preferred treatment option. However, the study found there were still 15%-35% of patients at
risk of AF recurrence. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been
widely used for the treatment of type 2 diabetes mellitus and heart failure. Nonetheless, it
remains unknown whether dapagliflozin can improve the recurrence of AF and reduces adverse
cardiovascular events for patients who need CMIV ablation, and whether it can be routinely
used for AF patients without diabetes or heart failure. Therefore, this study aims to explore
the effect of postoperative oral dapagliflozin on the recurrence of AF after CMIV.